Search results

Evidence-based recommendations on atidarsagene autotemcel (Libmeldy) for treating metachromatic leukodystrophy in children

Type

Highly specialised technologies guidance

Published

28 March 2022

Evidence-based recommendations on elosulfase alfa (Vimizim) for treating mucopolysaccharidosis type 4A in people of all ages

Type

Highly specialised technologies guidance

Published

20 April 2022

Evidence-based recommendations on selumetinib (Koselugo) for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 and over

Type

Highly specialised technologies guidance

Published

05 May 2022

Evidence-based recommendations on Sleepio to treat insomnia and insomnia symptoms

Type

Medical technologies guidance

Published

20 May 2022

Evidence-based recommendations on myCOPD for managing chronic obstructive pulmonary disease

Type

Medical technologies guidance

Published

31 March 2022

Evidence-based recommendations on UroShield for preventing catheter-associated urinary tract infections

Type

Medical technologies guidance

Published

31 March 2022

Evidence-based recommendations on Peristeen Plus transanal irrigation system for managing bowel dysfunction

Type

Medical technologies guidance

Last updated

06 June 2022

Evidence-based recommendations on Thopaz+ for managing chest drains

Type

Medical technologies guidance

Last updated

06 June 2022

Evidence-based recommendations on tucatinib (TUKYSA) for HER2 positive locally advanced or metastatic breast cancer in adults after 2 or more anti HER2 treatment therapies

Type

Technology appraisal guidance

Published

27 April 2022

Evidence-based recommendations on venetoclax (Venclyxto) with low dose cytarabine for untreated acute myeloid leukaemia in adults when intensive chemotherapy is unsuitable

Type

Technology appraisal guidance

Published

27 April 2022

Evidence-based recommendations on avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy in adults

Type

Technology appraisal guidance

Published

11 May 2022

Evidence-based recommendations on tepotinib (Tepmetko) for treating advanced non-small-cell lung cancer (NSCLC) with MET gene alterations in adults

Type

Technology appraisal guidance

Published

18 May 2022

Evidence-based recommendations on daratumumab (Darzalex) for relapsed and refractory multiple myeloma in adults

Type

Technology appraisal guidance

Published

13 April 2022

Evidence-based recommendations on sotorasib (Lumykras) for previously treated KRAS G12C mutation-positive locally advanced or metastatic non-small-cell lung cancer in adults

Type

Technology appraisal guidance

Published

30 March 2022

NICE is unable to make a recommendation on tagraxofusp (Elzonris) for treating blastic plasmacytoid dendritic cell neoplasm. This is because Stemline Therapeutics did not provide an evidence submission

Type

Technology appraisal guidance

Published

30 March 2022

Evidence-based recommendations on niraparib (Zejula) for treating relapsed, platinum-sensitive high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer in adults

Type

Technology appraisal guidance

Published

20 April 2022

NICE is unable to make a recommendation on nivolumab (Opdivo) with cabozantinib for untreated advanced renal cell carcinoma. This is because Bristol Myers Squibb withdrew the evidence submission. We will review this decision if the company decides to make a submission

Type

Technology appraisal guidance

Published

20 April 2022

NICE is unable to make a recommendation on TYRX Absorbable Antibacterial Envelope for preventing infection from cardiac implantable electronic devices because Medtronic withdrew its evidence submission

Type

Technology appraisal guidance

Published

25 May 2022

Evidence-based recommendations on romosozumab (EVENITY) for severe osteoporosis in people after menopause who are at high risk of fracture

Type

Technology appraisal guidance

Published

25 May 2022

Evidence-based recommendations on filgotinib (Jyseleca) for moderately to severely active ulcerative colitis in adults when conventional or biological treatment cannot be tolerated, or the disease has responded inadequately or lost response to treatment

Type

Technology appraisal guidance

Published

01 June 2022

NICE is unable to make a recommendation on anifrolumab (Saphnelo) for active autoantibody-positive systemic lupus erythematosus. This is because AstraZeneca did not provide an evidence submission. We will review this decision if the company decides to make a submission

Type

Technology appraisal guidance

Published

08 June 2022

Evidence-based recommendations on diroximel fumarate (Vumerity) for active relapsing–remitting multiple sclerosis in adults

Type

Technology appraisal guidance

Published

08 June 2022

Evidence-based recommendations on ibrutinib (Imbruvica) for Waldenstrom’s macroglobulinaemia in adults who have had at least 1 previous therapy

Type

Technology appraisal guidance

Published

08 June 2022

Evidence-based recommendations on venetoclax (Venclyxto) for chronic lymphocytic leukaemia in adults

Type

Technology appraisal guidance

Published

15 June 2022

NICE is unable to make a recommendation on enfortumab vedotin (Padcev) for previously treated locally advanced or metastatic urothelial cancer. This is because Astellas did not provide an evidence submission. We will review this decision if the company decides to make a submission

Type

Technology appraisal guidance

Published

15 June 2022

Evidence-based recommendations on durvalumab (Imfinzi) for locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation in adults

Type

Technology appraisal guidance

Published

22 June 2022